Kazia Therapeutics (KZIA) Cash & Equivalents (2009 - 2025)

Kazia Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $45.6 million for Q4 2025.

• Quarterly Cash & Equivalents rose 2175.82% year-over-year to $45.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $45.6 million (up 2175.82% YoY) and the FY2025 annual result came in at $2.8 million, up 148.36% from the prior year.
• Cash & Equivalents was $45.6 million for Q4 2025 at Kazia Therapeutics, up from $2.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $45.6 million in Q4 2025 and bottomed at $1.1 million in Q2 2024.
• A 5-year average of $9.8 million and a median of $3.2 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 75.18% — and 2025, when it soared 2175.82%.
• Kazia Therapeutics' Cash & Equivalents stood at $11.1 million in 2021, then plunged by 73.93% to $2.9 million in 2022, then fell by 19.6% to $2.3 million in 2023, then decreased by 13.59% to $2.0 million in 2024, then surged by 2175.82% to $45.6 million in 2025.
• Business Quant data shows KZIA's Cash & Equivalents at $45.6 million in Q4 2025, $2.8 million in Q2 2025, and $2.0 million in Q4 2024.